7,270 Shares in Insulet Corporation $PODD Purchased by Bank of Nova Scotia

Bank of Nova Scotia purchased a new stake in Insulet Corporation (NASDAQ:PODD) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,270 shares of the medical instruments supplier’s stock, valued at approximately $1,107,000.

A number of other institutional investors also recently made changes to their positions in PODD. Elevation Point Wealth Partners LLC acquired a new stake in shares of Insulet during the second quarter worth approximately $218,000. Commerce Bank bought a new position in Insulet during the 2nd quarter valued at $1,510,000. Northwestern Mutual Wealth Management Co. bought a new position in Insulet during the 2nd quarter valued at $127,000. Quantbot Technologies LP acquired a new position in Insulet during the 2nd quarter worth $291,000. Finally, Evolve Private Wealth LLC acquired a new position in Insulet during the 2nd quarter worth $523,000.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $143.38 on Thursday. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. Insulet Corporation has a fifty-two week low of $126.40 and a fifty-two week high of $354.88. The firm has a 50-day simple moving average of $154.52 and a 200 day simple moving average of $182.09. The company has a market cap of $9.94 billion, a PE ratio of 26.80, a P/E/G ratio of 1.13 and a beta of 1.10.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. During the same quarter last year, the company posted $1.17 earnings per share. Insulet’s revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, sell-side analysts anticipate that Insulet Corporation will post 6.51 EPS for the current year.

Insider Activity

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.36% of the company’s stock.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s second-quarter results exceeded expectations, with adjusted EPS of $1.66 versus the $1.47 consensus and revenue of $801.7 million versus estimates of $787.4 million. Revenue increased 23.5% year over year, although investors remain focused on whether the company can sustain growth after its 2026 guidance reset. Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?
• Neutral Sentiment: Insulet is scheduled to participate in the Wells Fargo 21st Annual Healthcare Conference, giving management an opportunity to address Omnipod demand, retention trends, manufacturing quality and its revised outlook. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: Kestra Medical Technologies appointed Curtis Kopf, Insulet’s former global customer-experience executive, to a senior vice president role. The move is not an operating announcement from Insulet, but could draw attention to executive talent movement and customer-support capabilities in the diabetes-device market. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Multiple law firms are publicizing a federal securities class action against Insulet and certain officers, with an August 31 lead-plaintiff deadline. The complaints allege that the company made misleading statements or failed to disclose material information concerning manufacturing controls, product safety and compliance. The lawsuits are allegations, not established findings, but they increase legal, reputational and potential regulatory risks. Faruqi & Faruqi Insulet Securities Class Action Notice
• Negative Sentiment: Investor notices link the lawsuit to two voluntary Omnipod recalls or medical-device corrections affecting approximately 7 million Pods. Analysts reportedly questioned the scope of Insulet’s manufacturing and quality-control problems, cut valuation assumptions and reduced estimates despite management reiterating guidance. These issues threaten investor confidence in the company’s manufacturing story and could lead to additional scrutiny or costs. PODD Shareholder Alert from Levi & Korsinsky

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on PODD shares. Raymond James Financial restated an “outperform” rating and issued a $180.00 target price on shares of Insulet in a research note on Thursday, August 6th. Sanford C. Bernstein decreased their price target on Insulet from $200.00 to $175.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Truist Financial reissued a “hold” rating and issued a $153.00 price objective (down from $210.00) on shares of Insulet in a report on Wednesday, August 5th. UBS Group cut their price objective on Insulet from $174.00 to $150.00 and set a “neutral” rating on the stock in a research note on Thursday, August 6th. Finally, Wall Street Zen downgraded Insulet from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 9th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $195.40.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.